Abstract
Between 50,000 and 60,000 mutations have been described in various genes that are associated with a wide variety of diseases. Reporting, storing and analysing these data is an important challenge as such data provide invaluable information for both clinical medicine and basic science. Locus-specific databases have been developed to exploit this huge volume of data. The p53 mutation database is a paradigm, as it constitutes the largest collection of somatic mutations (22,000). However, there are several biases in this database that can lead to serious erroneous interpretations. We describe several rules for mutation database management that could benefit the entire scientific community.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
MDMX elevation by a novel Mdmx–p53 interaction inhibitor mitigates neuronal damage after ischemic stroke
Scientific Reports Open Access 06 December 2022
-
Precise tumor immune rewiring via synthetic CRISPRa circuits gated by concurrent gain/loss of transcription factors
Nature Communications Open Access 18 March 2022
-
Regulation of p53 by the 14-3-3 protein interaction network: new opportunities for drug discovery in cancer
Cell Death Discovery Open Access 16 November 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Collins, F. S. Positional cloning moves from perditional to traditional. Nature Genet. 9, 347–350 (1995).
Cotton, R. G. Mutation detection 2001: novel technologies, developments and applications for analysis of the human genome. Hum. Mutat. 19, 313–314 (2002).
Paalman, M. H., Cotton, R. G. & Kazazian, H. H. Jr . Variation, databases, and disease: new directions for human mutation. Hum. Mutat. 16, 97–98 (2000).
Claustres, M., Horaitis, O., Vanevski, M. & Cotton, R. G. Time for a unified system of mutation description and reporting: a review of locus-specific mutation databases. Genome Res. 12, 680–688 (2002).
Montesano, R., Hainaut, P. & Wild, C. P. Hepatocellular carcinoma: from gene to public health. J. Natl Cancer Inst. 89, 1844–1851 (1997).
Mulligan, L. M. et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363, 458–460 (1993).
Hofstra, R. M. et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367, 375–376 (1994).
Xue, F. et al. Germline RET mutations in MEN 2A and FMTC and their detection by simple DNA diagnostic tests. Hum. Mol. Genet. 3, 635–638 (1994).
Edery, P. et al. Mutations of the RET proto-oncogene in Hirschsprung's disease. Nature 367, 378–380 (1994).
Romeo, G. et al. Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease. Nature 367, 377–378 (1994).
Olschwang, S. et al. Restriction of ocular fundus lesions to a specific subgroup of APC mutations in adenomatous polyposis coli patients. Cell 75, 959–968 (1993).
Spirio, L. et al. Alleles of the APC gene: an attenuated form of familial polyposis. Cell 75, 951–957 (1993).
Gallou, C. et al. Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC. Hum. Mutat. 13, 464–475 (1999).
Pearson, P. L. The genome data base (GDB) — human gene mapping repository. Nucleic Acids Res. 19 (Suppl.), 2237–2239 (1991).
Bilofsky, H. S. et al. The GenBank genetic sequence databank. Nucleic Acids Res. 14, 1–4 (1986).
Hamm, G. H. & Cameron, G. N. The EMBL data library. Nucleic Acids Res. 14, 5–9 (1986).
Bairoch, A. & Boeckmann, B. The SWISS-PROT protein sequence data bank. Nucleic Acids Res. 19 (Suppl.), 2247–2249 (1991).
Merali, Z. & Giles, J. Databases in peril. Nature 435, 1010–1011 (2005).
Horaitis, O. & Cotton, R. G. The challenge of documenting mutation across the genome: the human genome variation society approach. Hum. Mutat. 23, 447–452 (2004).
Stenson, P. D. et al. Human Gene Mutation Database (HGMD): 2003 update. Hum. Mutat. 21, 577–581 (2003).
Béroud, C., Collod- Béroud, G., Boileau, C., Soussi, T. & Junien, C. UMD (Universal Mutation Database): a generic software to build and analyze locus-specific databases. Hum. Mutat. 15, 86–94 (2000).
Béroud, C. & Soussi, T. p53 and APC gene mutations: software and databases. Nucleic Acids Res. 25, 138–138 (1997).
Wautot, V. et al. Germline mutation profile of MEN1 in multiple endocrine neoplasia type 1: search for correlation between phenotype and the functional domains of the MEN1 protein. Hum. Mutat. 20, 35–47 (2002).
Béroud, C. et al. Software and database for the analysis of mutations in the VHL gene. Nucleic Acids Res. 26, 256–258 (1998).
Jeanpierre, C., Béroud, C., Niaudet, P. & Junien, C. Software and database for the analysis of mutations in the human WT1 gene. Nucleic Acids Res. 26, 271–274 (1998).
Collod, G., Béroud, C., Soussi, T., Junien, C. & Boileau, C. Software and database for the analysis of mutations in the human FBN1 gene. Nucleic Acids Res. 24, 137–140 (1996).
Varret, M. et al. Software and database for the analysis of mutations in the human LDL receptor gene. Nucleic Acids Res. 25, 172–180 (1997).
Lamlum, H. et al. The type of somatic mutation at APC in familial adenomatous polyposis is determined by the site of the germline mutation: a new facet to Knudson's 'two-hit' hypothesis. Nature Med. 5, 1071–1075 (1999).
Al-Tassan, N. et al. Inherited variants of MYH associated with somatic G:C→T:A mutations in colorectal tumors. Nature Genet. 30, 227–232 (2002).
Soussi, T. The p53 tumour suppressor gene: a model for molecular epidemiology of human cancer. Mol. Med. Today 2, 32–37 (1996).
Harris, C. C. p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology, and cancer risk assessment. Environ. Health Perspect. 104, 435–439 (1996).
Nelson, D. R. 'A variant of uncertain significance' and the proliferation of human disease gene databases. Hum. Genomics 2, 70–74 (2005).
Rodin, S. N., Holmquist, G. P. & Rodin, A. S. CPG transition strand asymmetry and hitch-hiking mutations as measures of tumorigenic selection in shaping the p53 mutation spectrum. Int. J. Mol. Med. 1, 191–199 (1998).
Futreal, P. A. et al. A census of human cancer genes. Nature Rev. Cancer 4, 177–183 (2004).
Morral, N. et al. The origin of the major cystic fibrosis mutation (ΔF508) in European populations. Nature Genet. 7, 169–175 (1994).
Beroud, C. et al. UMD (Universal Mutation Database): 2005 update. Hum. Mutat. 26, 184–191 (2005).
Brown, A. F. & McKie, M. A. MuStaR and other software for locus-specific mutation databases. Hum. Mutat. 15, 76–85 (2000).
Fokkema, I. F., den Dunnen, J. T. & Taschner, P. E. LOVD: easy creation of a locus-specific sequence variation database using an 'LSDB-in-a-box' approach. Hum. Mutat. 26, 63–68 (2005).
den Dunnen, J. T. & Antonarakis, S. E. Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum. Mutat. 15, 7–12 (2000).
Maurer, S. M., Hugenholtz, P. B. & Onsrud, H. J. Intellectual property. Europe's database experiment. Science 294, 789–790 (2001).
Greenbaum, D. & Gerstein, M. A universal legal framework as a prerequisite for database interoperability. Nature Biotechnol. 21, 979–982 (2003).
Soussi, T. & Béroud, C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nature Rev. Cancer 1, 233–240 (2001).
Soussi, T. & Béroud, C. Significance of TP53 mutations in human cancer: a critical analysis of mutations at CpG dinucleotides. Hum. Mutat. 21, 192–200 (2003).
Bitton, A., Neuman, M. D. & Glantz, S. A. The p53 tumour suppressor gene and the tobacco industry: research, debate and conflict of interest. Lancet 365, 1–10 (2005).
Kato, S. et al. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc. Natl Acad. Sci. USA 100, 8424–8429 (2003).
Soussi, T., Kato, S., Levy, P. P. & Ishioka, C. Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations. Hum. Mutat. 25, 6–17 (2005).
Krawczak, M. & Cooper, D. N. p53 mutations, benzo[a]pyrene and lung cancer. Mutagenesis 13, 319–320 (1998).
Phelan, C. M. et al. Classification of BRCA1 missense variants of unknown clinical significance. J. Med. Genet. 42, 138–146 (2005).
Fleming, M. A., Potter, J. D., Ramirez, C. J., Ostrander, G. K. & Ostrander, E. A. Understanding missense mutations in the BRCA1 gene: an evolutionary approach. Proc. Natl Acad. Sci. USA 100, 1151–1156 (2003).
Tornaletti, S. & Pfeifer, G. P. Complete and tissue-independent methylation of CpG sites in the p53 gene: implications for mutations in human cancers. Oncogene 10, 1493–1499 (1995).
You, Y. H., Li, C. & Pfeifer, G. P. Involvement of 5-methylcytosine in sunlight-induced mutagenesis. J. Mol. Biol. 293, 493–503 (1999).
Denissenko, M. F., Chen, J. X., Tang, M. S. & Pfeifer, G. P. Cytosine methylation determines hot spots of DNA damage in the human p53 gene. Proc. Natl Acad. Sci. USA 94, 3893–3898 (1997).
Soussi, T. et al. Meta-analysis of the p53 mutation database for mutant p53 biological activity reveals a methodological bias in mutation detection. Clin. Cancer Res. (in the press).
Acknowledgements
Development of the UMD software is supported by grants from AFM to C.B. and M.C. Work of T.S. is supported by the ARC and ligue contre le cancer (comité de Paris). We are grateful to Richard Cotton for critical reading of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Related links
Related links
DATABASES
National Cancer Institute
OMIM
FURTHER INFORMATION
Mutation Storage and Retrieval Program
Leiden Open Source Variation Database
p53 database of the International Agency for Research on Cancer
Rights and permissions
About this article
Cite this article
Soussi, T., Ishioka, C., Claustres, M. et al. Locus-specific mutation databases: pitfalls and good practice based on the p53 experience. Nat Rev Cancer 6, 83–90 (2006). https://doi.org/10.1038/nrc1783
Issue Date:
DOI: https://doi.org/10.1038/nrc1783
This article is cited by
-
Precise tumor immune rewiring via synthetic CRISPRa circuits gated by concurrent gain/loss of transcription factors
Nature Communications (2022)
-
MDMX elevation by a novel Mdmx–p53 interaction inhibitor mitigates neuronal damage after ischemic stroke
Scientific Reports (2022)
-
Regulation of p53 by the 14-3-3 protein interaction network: new opportunities for drug discovery in cancer
Cell Death Discovery (2020)
-
The atypical cyclin-like protein Spy1 overrides p53-mediated tumour suppression and promotes susceptibility to breast tumourigenesis
Breast Cancer Research (2019)
-
Low expression of long noncoding RNA PANDAR predicts a poor prognosis of non-small cell lung cancer and affects cell apoptosis by regulating Bcl-2
Cell Death & Disease (2015)